| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | DA709Q5020 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Epidermal growth factor receptor erbB1 antagonist | PubMed |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Head and Neck Neoplasms | 3 | D006258 | ClinicalTrials |
| Carcinoma, Squamous Cell | 3 | D002294 | ClinicalTrials |
| Head and Neck Neoplasms | 3 | D006258 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 2 | D002289 | ClinicalTrials |
| Colorectal Neoplasms | 1 | D015179 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 667901-13-5 |
| ChEMBL | CHEMBL2107861 |
| FDA SRS | DA709Q5020 |
CONTENTS